Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Eli Lilly $1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0…
NeoGenomics $300 million offerings of stock and convertible senior notes
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by…
Envision Healthcare $106 million exchange offer
Davis Polk advised the dealer manager in connection with the private offer by Envision Healthcare Corporation to exchange…
Aeglea BioTherapeutics $138 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and…
Biogen $3 billion senior notes offering
Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of…
Akeso HK$2.44 billion IPO
Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the…
Coherus BioSciences $200 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus…
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189…
InnoCare Pharma HK$2.24 billion IPO
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock…